Home
FUJI YAKUHIN

FUJI YAKUHIN Market Share Analysis for November 2025

富士薬品は、総合医薬品企業を目指し、置き薬・配置薬を中心に、医薬品の製造・販売・研究開発を行います。

Health > Biotechnology and Pharmaceuticals

Domainfujiyakuhin.co.jp

Year Founded--

Employees> 10001

Annual Revenue$50M - $75M

FUJI YAKUHIN

FUJI YAKUHIN (including company regionals)

fujiyakuhin.co.jp

See more website traffic and engagement information

FUJI YAKUHIN Revenue up to November 2025 is 50M - 75M

revenue generated by FUJI YAKUHIN top domains

FUJI YAKUHIN top domains revenue over 3 years

Revenue for FUJI YAKUHIN top domains

fujiyakuhin.co.jp50M - 75M

See more with Sales Intelligence

Total visits to FUJI YAKUHIN's top domains

Understand FUJI YAKUHIN market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

fujiyakuhin.co.jp159.1K

See more with Sales Intelligence

Avg. visit duration in FUJI YAKUHIN's top domains

Analyze FUJI YAKUHIN engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

fujiyakuhin.co.jp00:01:10

See more with Sales Intelligence

Avg. pageviews on FUJI YAKUHIN's top domains

See how FUJI YAKUHIN keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

fujiyakuhin.co.jp2.57

See more with Sales Intelligence

FUJI YAKUHIN top competitors by domain

Top similar sites in November 2025, ranked by their affinity

fujipharma.jpCompany NameFuji Pharma Co., Ltd.Employees1001 - 5000HQJapan, SanbanchouAnnual revenue$200M - $500MTotal visits30.6KHealth > Biotechnology and Pharmaceuticals

Top technologies used by FUJI YAKUHIN

These are the website technologies, by industry, used by FUJI YAKUHIN top domains

Advertising (10)

Google Adsense

Social (10)

Google+ Platform

Payment & Currencies (8)

Visa

Conversion & Analytics (4)

Google Analytics

More Technologies

9

See all

News & Signals from FUJI YAKUHIN

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsFuji Yakuhin sold assets to Urica Therapeutics, Inc. on Jan 1st '23.Urica Therapeutics acquired North American and European rights to Dotinurad from Japan's Fuji Yakuhin in 2023 and subsequently partnered with Crystalys Therapeutics to advance its global development.

NewsFuji Yakuhin sells assets to Eisai.Based on this agreement, Eisai will acquire exclusive development and marketing rights for dotinurad in China from FUJI YAKUHIN.